Next-Generation Assessment of ERBB2 Amplification Status

Establishing ERBB2 [human epidermal growth factor receptor 2 (HER2)] amplification status in breast and gastric carcinomas is essential to treatment selection. Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) constitute the current standard for assessment. With further advancements in genomic medicine, new clinically relevant biomarkers are rapidly emerging and options for targeted therapy are increasing in patients with advanced disease, driving the need for comprehensive molecular profiling.

http://jmd.amjpathol.org/article/S1525-1578(16)30233-1/fulltext?rss=yes

Source: Journal of Molecular Diagnostics - December 23, 2016 Category: Pathology Authors: Dara S. Ross, Ahmet Zehir, Donavan T. Cheng, Ryma Benayed, Khedoudja Nafa, Jaclyn F. Hechtman, Yelena Y. Janjigian, Britta Weigelt, Pedram Razavi, David M. Hyman, Jos é Baselga, Michael F. Berger, Marc Ladanyi, Maria E. Arcila Tags: Regular Article Source Type: research